Cancer continues to be one of the biggest health risks your clients face — and one of the leading drivers of life insurance death claims. Traditional screenings like mammograms and colonoscopies have absolutely moved the needle, but they only cover a few of the many and various cancer types.

That's why multicancer early detection (MCED) tests are getting so much attention today. These tests promise something we've never had before: the ability to screen for dozens of cancers with a simple blood draw, often long before symptoms show up.

For financial professionals and life insurance agents, this isn't just a medical breakthrough — it's a conversation changer. MCED is poised to influence how clients think about longevity, wellness, and risk, and it may eventually reshape underwriting practices. Staying informed about this trend positions you as a trusted professional in a rapidly evolving landscape. 

Think of MCED tests as next‑generation liquid biopsies. Instead of looking for a single cancer, they scan the blood for molecular breadcrumbs — DNA methylation patterns, circulating tumor DNA (ctDNA), RNA signals, proteins — that may indicate a cancer signal somewhere in the body.

Machine learning models analyze those signals and estimate whether cancer might be present and, if so, where it likely started.

A key point for clients: MCED tests don't diagnose cancer. They're an early warning system that helps clinicians decide whether further targeted diagnostic testing is needed, before any symptoms actually appear.

MCED results are straightforward:

• No cancer signal detected
• Cancer signal detected, often with a predicted tissue of origin

A positive result doesn't mean someone has cancer — it simply means additional testing is indicated. And a negative result doesn't guarantee someone is cancer‑free, especially in very early stages.

"Specificity" and "Sensitivity"¹ describe the accuracy of a test that reports the presence or absence of a medical condition.  Specificity is a measure of how well a test can identify true negatives, and sensitivity is a measure of how well a test can identify true positives.

With MCED tests, specificity (correctly identifying people who do not have an active cancer signal) is extremely high (around 99%), which helps minimize false positives. Sensitivity varies by cancer type and stage, and, as you would expect, improves as cancers progress. 

Cancer drives roughly half of life insurance death claims, so anything that helps detect it earlier has major implications for the industry.  MCED tests offer insurers a way to engage policyholders post-issue, improve transparency, and potentially reduce late-stage claims.

Munich Re is already piloting MCED programs as value‑added services for policyholders, and John Hancock offers the GRAIL Galleri MCED test as part of their Vitality program reinforcing wellness and strengthening client relations. Actuarial models suggest these tests could shift mortality assumptions downward, though over-diagnosis and earlier incidence require careful modeling.

For you, MCED represents an opportunity to elevate the conversation beyond product performance, and instead focus on more personal concerns of your client:  wellness, prevention, and long‑term financial security. 

Pros

• Detects a broad range of cancers, including those without routine screening
• Very high specificity (~99%), reducing false positives
• Simple blood draw — easy and accessible for most clients
• Adds tangible value to wellness‑focused insurance programs

Cons

• Lower sensitivity for early‑stage cancers
• False positives can create anxiety and lead to additional testing
• Cost remains high ($500–$1,000) with limited insurance coverage
• Regulatory pathways and follow‑up protocols are still developing

The technology is advancing fast. Researchers are applying multi‑omics (i.e., integrating data from various biological layers), refining machine‑learning models, and running large‑scale trials like PATHFINDER 2, a major clinical trial evaluating the Galleri multi-cancer early detection blood test, to determine whether MCED actually effectively detects cancer and predicts its origin, with the potential for reducing mortality.

Regulators and those who ultimately pay for the services will want strong real‑world evidence before widespread adoption, but momentum is building. As the science matures, MCED could become a standard part of preventive care — and a meaningful differentiator in life insurance value‑added services. 

MCED tests represent one of the most promising shifts in preventive health we've seen in years. For the life insurance world, they offer a new way to help clients stay healthier longer, deepen engagement, and reinforce the industry's commitment to wellness and longevity.

Yes, there are limitations — cost, sensitivity, and follow‑up pathways still need work. But for financial professionals and agents, the real opportunity lies in understanding how MCED fits into the bigger picture of risk management and long‑term planning.

Those who can speak confidently about these innovations will be better positioned to lead client conversations, differentiate their practice, and deliver greater value in a world where health and financial security are more connected than ever.